A Phase 1 interventional study of Gold seeds insertion to detect movements at pelvis and Image guided MRI based RT (IMRT+Brachytherapy) in Integrated MRI Based RT as Standard of Care and Locally Advanced Cervical Cancer, sponsored by AHS Cancer Control Alberta. Withdrawn. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-02-25.
Sponsored by AHS Cancer Control Alberta · Phase 1, Interventional, and Treatment
Main cause of mortality in cervix cancer is local relapse in the pelvis. Since distant metastasis is quiet rare, increasing local control in the pelvis can directly translate into improvement in survival. Obstacles in front of this approach is the dose limitation to normal organs located in the pelvis adjacent to the tumor. 3-D MRI based EBRT and Brachytherapy will grant safe delivery of more conformal higher doses of radiation to the tumor and allowing sparing of the normal structures.
A total of 10 patients with a diagnosis of locally advanced cervical carcinoma will be enrolled. After diagnosis and written informed consent, patients will undergo investigations prior to treatment planning, including CT imaging as per standard of care. In addition, patients will have an MRI of the pelvis + PET scan + EUA and gold seeds insertion to verify pelvic organs movement and EB-IMRT with daily cone beam CT. Brachytherapy treatment planning will be based on MRI imaging with the applicator in situ.
1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.
Browse Uterine Cervical Neoplasms studies →AHS Cancer Control Alberta is the lead sponsor of 182 studies on the registry; 31 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Feasibility parameters
Time frame: One year
Response rate, acute and late toxicity, local control rate, survival
Time frame: Five years
Dosimetric comparison between 2D and 3D Brachytherapy treatment planning
No study locations are listed for this record.
This study is withdrawn, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AHS Cancer Control Alberta